Fluticasone Furoate/Umeclidinium/Vilanterol Initiation Following a COPD Exacerbation: Benefits of Prompt Initiation on COPD Outcomes
Healthcare providers should consider the positive impact of prompt FF/UMEC/VI initiation on exacerbation rate, hospital readmission rate, and costs when treating patients with COPD at risk of exacerbations.
Authors
- Ana Urosevic
- François Laliberté (ORCID: https://orcid.org/0000-0003-2601-6214)
- Rosirene Paczkowski (ORCID: https://orcid.org/0009-0001-7151-4311)
- Guillaume Germain (ORCID: https://orcid.org/0000-0002-4525-7673)
- Stephen G. Noorduyn (ORCID: https://orcid.org/0000-0002-5936-5579)
- David M. Mannino (ORCID: https://orcid.org/0000-0003-3646-7828)
- Kristi DiRocco (ORCID: https://orcid.org/0009-0006-2988-5684)
Institutions
- University of Kentucky (US)
- Providence College (US)
- South College (US)
- GlaxoSmithKline (United States) (US)
- Thumbay Group (United Arab Emirates) (AE)
- Impact (CA)
- McMaster University (CA)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1007/s12325-024-02999-3
- Citations
- 3
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 1.26